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Abstract
IMPORTANCE The current diagnostic pathway for patients with suspected prostate cancer (PCa)
includes prostate biopsy. A large proportion of individuals who undergo biopsy have either no PCa or
low-risk disease that does not require treatment. Unnecessary biopsies may potentially be avoided
with prebiopsy imaging.
OBJECTIVE To compare the performance of systematic transrectal ultrasonography–guided
prostate biopsy vs prebiopsy biparametric or multiparametric magnetic resonance imaging (MRI)
followed by targeted biopsy with or without systematic biopsy.
DATA SOURCES MEDLINE, Embase, Cochrane, Web of Science, clinical trial registries, and reference
lists of recent reviewswere searched throughDecember 2018 for randomized clinical trials using the
terms “prostate cancer” and “MRI.”
STUDY SELECTION Randomized clinical trials comparing diagnostic pathways including prebiopsy
MRI vs systematic transrectal ultrasonography–guided biopsy in biopsy-naive men with a clinical
suspicion of PCa.
DATA EXTRACTIONAND SYNTHESIS Data were pooled using random-effects meta-analysis. Risk
of bias was assessed using the revised Cochrane tool. Preferred Reporting Items for Systematic
Reviews andMeta-analyses (PRISMA) guidelines were followed. All review stages were conducted by
2 reviewers.
MAINOUTCOMES ANDMEASURES Detection rate of clinically significant and insignificant PCa,
number of biopsy procedures, number of biopsy cores taken, and complications.
RESULTS Seven high-quality trials (2582 patients) were included. Compared with systematic
transrectal ultrasonography–guided biopsy alone, MRI with or without targeted biopsy was
associated with a 57% (95% CI, 2%-141%) improvement in the detection of clinically significant PCa,
a 33% (95%CI, 23%-45%) potential reduction in the number of biopsy procedures, and a 77% (95%
CI, 60%-93%) reduction in the number of cores taken per procedure. One trial showed reduced pain
and bleeding adverse effects. Systematic sampling of the prostate in addition to the acquisition of
targeted cores did not significantly improve the detection of clinically significant PCa compared with
systematic biopsy alone.
(continued)
Key Points
Question Is prebiopsy magnetic
resonance imaging combined with
targeted biopsy associated with
improved detection of clinically
significant prostate cancer compared
with transrectal ultrasonography–
guided systematic prostate
biopsy alone?
Findings This systematic review and
meta-analysis of 7 randomized clinical
trials (2582 patients) demonstrates that
prebiopsymagnetic resonance imaging
combined with targeted biopsy is
associated with improved detection of
clinically significant prostate cancer and
reduced numbers of biopsy cores per
procedure, while potentially avoiding
unnecessary biopsies.
Meaning These findings support the
introduction of prebiopsy magnetic
resonance imaging into the diagnostic
pathway for biopsy-naive men with
suspected prostate cancer.
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Abstract (continued)
CONCLUSIONS ANDRELEVANCE In this meta-analysis, prebiopsyMRI combined with targeted
biopsy vs systematic transrectal ultrasonography–guided biopsy alone was associated with improved
detection of clinically significant PCa, despite substantial heterogeneity among trials. PrebiopsyMRI
was associated with a reduced number of individual biopsy cores taken per procedure and with
reduced adverse effects, and it potentially prevented unnecessary biopsies in some individuals. This
evidence supports implementation of prebiopsy MRI into diagnostic pathways for suspected PCa.
JAMA Network Open. 2019;2(8):e198427. doi:10.1001/jamanetworkopen.2019.8427
Introduction
Prostate cancer (PCa) is the most commonly diagnosed cancer in men and the second leading cause
of cancer-associated death among men in the United States.1 Despite this statistic, a large number
of PCas are not clinically significant and are unlikely to lead to problems if left untreated.2
Distinguishing high-risk from low-risk PCa remains difficult,3 leading to overdiagnosis and, for some
men, unnecessary invasive treatments and treatment-associated morbidity.4 There is, therefore, an
unmet clinical need to develop tests that can detect clinically significant PCa (csPCa) while reducing
overdiagnosis of low-risk disease.
Clinical findings of possible PCa include elevated prostate-specific antigen (PSA) levels and/or
abnormal digital rectal examination findings. The US Preventive Services Task Force,5 European
Association of Urology,6 and UK National Institute for Health and Care Excellence7 recommend
transrectal ultrasonography (TRUS)–guided biopsy as a standard investigation in the diagnosis of
PCa. Transrectal ultrasonography is primarily used for anatomical guidance during biopsy, with
approximately 10 to 14 individual biopsy cores taken systematically from the prostate (depending on
the gland volume). However, a TRUS-guided systematic biopsy predominantly samples the
peripheral zone of the prostate gland, so some PCa foci may bemissed or undersampled, leading to
disease misclassification and/or underdiagnosis.8
A recent development in the diagnostic pathway for suspected PCa involves prebiopsy
magnetic resonance imaging (MRI) using 2 or more parameters to identify suspicious areas.
Multiparametric MRI (mpMRI) uses T2-weighted, dynamic contrast-enhanced, and diffusion-
weighted imaging, whereas biparametric MRI only uses T2-weighted and diffusion-weighted
imaging. These MRI-visualized lesions are graded using the Prostate Imaging Reporting and Data
System9 and can be specifically targeted at biopsy. This method offers potential advantages over a
pathway where only peripheral zone cores are taken systematically without prior imaging, including
more-accurate detection of csPCa using targeted biopsy, the possibility of reducing the need for a
biopsy in some individuals with normal MRI findings, and a potential reduction in the number of
biopsy cores taken per procedure. Avoiding unnecessary biopsiesmay reduce serious adverse events
associated with this procedure, such as bleeding, sepsis, and, rarely, death.10 Fewer biopsy cores
being taken per procedure could reduce the total procedure time andmay reduce the risk of adverse
effects, making it a more acceptable investigation for patients.11 Previous studies12 have suggested
that using prebiopsy mpMRI to guide biopsies may increase the sensitivity to detect higher-grade
PCa appropriate for treatment. Prebiopsy mpMRI has recently been recommended in the United
Kingdom as the standard of care for biopsy-naive patients with suspected PCa.13
Evidence supporting the value of introducing MRI into the diagnostic pathway for suspected
PCa is increasing. Several randomized clinical trials (RCTs) have been conducted comparing a
systematic TRUS-guided biopsy pathway (ie, systematic biopsy alone) with pathways including a
prebiopsy MRI. We conducted a systematic review of these RCTs and investigated 2 different
prebiopsy MRI pathways: (1) prebiopsy MRI followed by a targeted biopsy only (ie, MRI plus targeted
biopsy pathway) and (2) prebiopsyMRI followed by a biopsy obtaining both targeted and systematic
biopsy cores (ie, MRI plus targeted and systematic biopsy pathway) (Figure 1). Our main outcome
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was the detection rate of csPCa. Secondary outcomes were the detection rate of any-grade PCa, the
number of biopsy procedures potentially avoided, the number of any-grade PCamissed byMRI, and
complications.
Methods
This review followed recommendedmethods for systematic reviews14,15 and is reported according to
the Preferred Reporting Items for Systematic Reviews andMeta-analyses (PRISMA) reporting guideline.
We expanded the data extraction and analysis, as described elsewhere,16 to differentiate between the
2 prebiopsy MRI pathways and to include the secondary outcome of PCamissed byMRI.
Data Sources and Study Selection
Randomized clinical trials including biopsy-naive menwith clinical suspicion for PCa that compared a
2-stepMRI pathway (prebiopsyMRI group)with TRUS-guided systematic biopsy (systematic biopsy
alone group) were eligible for inclusion. Eligible MRI pathways consisted of prebiopsy MRI using 2 or
more parameters, followed by a targeted biopsy with or without systematic sampling based on the
MRI results (MRI plus targeted biopsy or MRI plus targeted and systematic biopsy). MEDLINE,
Embase, Cochrane, andWeb of Science were searched through December 2018 using the terms
“prostate cancer” and “MRI” and an RCT filter.16 Trial registries and reference lists of recent reviews
were also searched. Abstracts and full texts were independently screened by 2 reviewers using
Rayyan.17 Any discrepancies between the reviewers were resolved through discussion or referral to a
third reviewer.
Data Extraction and Risk of Bias Assessment
Data were extracted by 1 author and checked by a second author using standardized data extraction
forms. Data on patient characteristics, study design, imaging, and biopsy protocols were extracted
according to the Standards of Reporting for MRI-Targeted Biopsy Studies recommendations.3 We
investigated 2 hypothetical prebiopsy MRI pathways and extracted data that allowed analysis of
these pathways (Figure 1): (1) where prebiopsy MRI–positive patients undergo targeted biopsy alone
(MRI plus targeted biopsy pathway), or (2) where prebiopsy MRI–positive patients undergo biopsy
including targeted and systematic cores (MRI plus targeted and systematic biopsy pathway). In RCTs
that investigated theMRI plus targeted and systematic biopsy pathway, but also reported data that
allowed deduction of outcomes for MRI plus targeted biopsy (ie, trials that reported results for the
targeted and systematic cores separately), data were extracted for both potential prebiopsy MRI
pathways. We extracted the number of patients with a diagnosis of csPCa or clinically insignificant
PCa according to the definition of clinical significance used in each RCT (eTable 1 in the Supplement).
Figure 1. Three Diagnostic Pathways Used to Detect Clinically Significant Prostate Cancer
Systematic biopsy
alone pathway
Patients with clinical
suspicion of prostate cancer
Systematic biopsy
MRI positive targeted and
systematic biopsy
Patients with clinical
suspicion of prostate cancer
MRI
MRI positive MRI negative
Targeted plus 
systematic biopsy
No biopsy
MRI positive
targeted biopsy
Patients with clinical 
suspicion of prostate cancer
MRI
MRI positive MRI negative
Targeted
biopsy
No biopsy
Flowcharts show, from left to right, a transrectal
ultrasonography–guided systematic biopsy alone
pathway (control), in which all patients with clinical
suspicion of prostate cancer undergo this procedure; a
magnetic resonance imaging (MRI) plus targeted
biopsy pathway, in which individuals with a positive
prebiopsy MRI undergo a transrectal ultrasonography–
guided targeted biopsy alone; and anMRI plus
targeted and systematic biopsy pathway, in which
individuals with positive prebiopsy MRI findings
undergo a transrectal ultrasonography–guided
targeted biopsy combined with a systematic biopsy. In
both hypothetical MRI pathways, individuals with
negative MRI findings do not undergo a prostate
biopsy procedure.
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The number of patients with negativeMRI findings was extracted to determine the number of biopsy
procedures that could potentially have been avoided. We also extracted information on those
cancers missed according to the systematic TRUS-guided biopsy or a reference standard, such as
prostatectomy or saturation biopsy. These numbers were used to calculate percentages of cancers
missed byMRI (ie, when theMRI findings were negative, but a cancer was subsequently identified at
systematic biopsy, prostatectomy, or saturation biopsy) or by targeted biopsy alone (ie, when the
targeted cores did not sample the cancer, but when themalignant neoplasmwas identified within
systematic cores). Risk of bias was assessed using the revised Cochrane tool (RoB 2.0 tool).18 Authors
were contacted to providemissing information.
Data Synthesis andAnalysis
Random-effects meta-analysis models were used to estimate summary effect estimates (risk ratios
and percentages) and to allow for variation among studies using the method of DerSimonian and
Laird.19 Heterogeneity was assessed using the I2 statistic.20 Ninety-five percent confidence intervals
around risk ratios were calculated using theWoolf method, and 95% confidence intervals around
percentages were calculated using the exact binomial (Clopper-Pearson) procedure.21 A P < .05 was
regarded as statistically significant (1-sided χ2 test). All analyses were performed in Stata statistical
software version 15.1 (StataCorp)22 using themetan andmetaprop commands.23,24
Summary risk ratios were estimated to compare the proportion of csPCas detected for each
prebiopsy MRI pathway (MRI plus targeted and systematic biopsy andMRI plus targeted biopsy)
comparedwith the systematic biopsy alone group.We stratified the analysis by biparametric MRI and
mpMRI given the fundamental differences in theseMRI techniques.We also estimated the summary
percentage of patients with negative MRI findings (ie, potential biopsies avoided) with any-grade
PCa and csPCa cases missed by prebiopsy MRI or targeted biopsy alone.
Results
The literature searches identified 1742 records, of which 7 RCTs fulfilled the inclusion criteria
(Figure 2): 6 original investigations25-30 and 1 conference abstract31 including 2582 patients in total.
In 5 RCTs,25-28,31 the clinical suspicion of PCa was based on elevated PSA levels, abnormal digital
rectal examination findings, or both. In 2 RCTs,29,30 patients with abnormal digital rectal examination
findings were excluded. Two RCTs25,29 applied an age restriction excluding patients older than 75
years. There were no significant differences in age, prostate volume, or prebiopsy PSA levels
Figure 2. Diagram of Inclusion Criteria for Randomized Clinical Trials
2374 Citations identified through 
database searching
289 Citations identified 
in trial registries
1742 Citations after duplicates 
removed
1742 Citations screened
45 Full-text articles assessed 
for eligibility
7 Included studies
1697 Citations excluded (exclusion 
by title or abstract)
38 Articles excluded
6
25
5
1
1
Ongoing trials
Not primary research
Duplicates
Incorrect population
Incorrect reference test
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between individuals in the prebiopsy MRI pathways and those in the systematic biopsy alone group,
although 1 trial27 did not report these measures (Table).
Several prebiopsy MRI pathways were used in the studies included in this analysis (Figure 3). In
all RCTs, individuals with a clinical suspicion of PCawere randomly allocated to either the systematic
biopsy alone group or to a prebiopsyMRI group. In all but 1 RCT,26 individuals with negative prebiopsy
MRI findings proceeded to undergo a systematic biopsy, with this procedure being identical to that
performed in the systematic biopsy alone group because there was no visible MRI lesion to be
sampled by a targeted approach. In 2 RCTs,26,29 individuals with positive MRI findings underwent a
targeted procedure alone (MRI plus targeted biopsy pathway), whereas in the other RCTs,25,27,28,30,31
individuals with positiveMRI findings underwent a combined procedure incorporating both targeted
and systematic cores (Figure 3). For 3 of the MRI plus targeted and systematic biopsy RCTs,25,28,30
it was possible to extract sufficient data regarding the content of the targeted cores. In 2 RCTs,25,28
targeted cores were also taken in patients within the systematic biopsy alone group if suspicious
lesions were visible at ultrasonography or palpable during digital rectal examination (Figure 3), which
may have increased PCa detection in the control group of these RCTs compared with the systematic
biopsy alone group of other RCTs.
Two RCTs25,29 used a 1.5-T MRI scanner, 4 RCTs27,28,30,31 used a 3.0-TMRI scanner, and 1 RCT25
included data from both 1.5- and 3.0-TMRI scanners. Three RCTs26,27,29 used a phased-array coil with
or without an endorectal coil, 1 RCT30 used body and spinematrix surface coils, 1 RCT31 used a
transrectal coil, 1 RCT25 did not use a coil, and 1 RCT28 did not report whether a coil was used. One
RCT25 used biparametric MRI, whereas the other RCTs usedmpMRI. Different definitions were used
to define a positive MRI, including a Prostate Imaging Reporting and Data System score of 3 or
higher,25,26,29 Prostate Imaging Reporting and Data System score of 4 or higher,31 or any lesion
detected at MRI without the use of a standardized reporting system (eTable 2 in the
Supplement).27,28,30 The images were interpreted by at least 1 experienced radiologist25,26,31 or were
assessed in consensus by 2 radiologists27,28,30 or 3 radiologists29 (eTable 1 in the Supplement).
Individuals in the prebiopsy MRI group with positive MRI findings underwent a targeted biopsy.
The number of cores sampled during this targeted procedure varied considerably among RCTs
(eTable 1 in the Supplement). For example, in 2 RCTs,25,27 a maximum of 2 cores were taken per
targeted biopsy, whereas in another RCT,26 a maximum of 4 cores were obtained from amaximum
of 3 areas, resulting in 1 to 12 cores per targeted procedure. The individuals randomized to the
systematic biopsy alone group underwent a standard TRUS-guided prostate biopsy systematically
sampling the peripheral zones of the prostate gland (eTable 1 in the Supplement) with 12 cores,25,29
14 cores,27 or 10 to 12 cores26,28,30 taken during the procedure. Most trials used only the transrectal
approach to perform targeted prostate biopsies;25,27,28,30,31 however, 2 trials26,29 used either the
transrectal or transperineal approach depending on local expertise or the anatomic location of the
radiological lesion. Transperineal approaches were used only in the MRI group of these studies,
whereas in the systematic biopsy alone group, all biopsies were performed using the transrectal
approach. Furthermore, the manner in which the prebiopsy MRI findings were used to guide the
targeted biopsy varied among RCTs. Four RCTs25,26,29,31 usedMRI-ultrasonography image fusion, 3
RCTs26,28,30 used cognitive guidance, and 1 RCT27 did not report themethod of biopsy guidance.
Individuals received a diagnosis of csPCa, clinically insignificant PCa, or no PCa, depending on
the biopsy pathologic results. The characterization of biopsy-detected PCa as being clinically
significant or insignificant depended on the Gleason sum score (6 or 7), maximum cancer core
length (3 or 5 mm), and/or the number of positive cores. (With the Gleason scoring system,
pathologists grade the cell patterns in the biopsy sample from 1 to 5, where grade 1 cells resemble
normal prostate tissue and grade 5 are high-risk cancerous cells. The Gleason score is calculated by
adding the grade of themost predominant pattern with the second-most predominant pattern, such
as 3 + 4.) However, no 2 studies used the same definition of csPCa (eTable 1 in the Supplement).
Five RCTs25,26,29,30 were judged to have a low overall risk of bias (eTable 3 in the Supplement).
Two RCTs27,31 were judged to have some concerns regarding the randomization process, one of
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which27 did not reportmethods of randomization, allocation concealment, or baseline characteristics
of each group; the other RCT31 did not report sufficient information to asses randomization.
Data from 5 RCTs24,27,28,30,31 contributed to the analysis of theMRI plus targeted and systematic
biopsy pathway, and data from 5 RCTs25,26,28-30 were used to analyze theMRI plus targeted biopsy
pathway (Figure 4). In 1 study,25 the use of prebiopsy biparametric MRI did not significantly improve
the detection of csPCa compared with the use of systematic biopsy alone (risk ratio, 0.78; 95% CI,
0.55-1.09). However, in 4 of the RCTs,26,28-30 the MRI plus targeted biopsy pathway improved the
detection of csPCa by 57% (95%CI, 2%-141%; risk ratio, 1.57; [95%CI, 1.02-2.41]; I2 = 71%) compared
with systematic biopsy alone. Compared with systematic biopsy alone, the MRI plus targeted and
systematic biopsy pathway did not significantly improve the detection of csPCa (risk ratio, 1.36; 95%
CI, 0.79-2.34; I2 = 87%) in 4 RCTs.27,28,30,31
Direct comparison between the 2 prebiopsy MRI pathways, using the 3 RCTs25,28,30 that
evaluated theMRI plus targeted and systematic biopsy pathway and reported separate data for the
targeted and systematic cores regarding PCa detection, showed mixed results. In 2 of these
RCTs,25,28 the additional acquisition of systematic cores did not identify additional csPCa cases
beyond those detected in the targeted cores alone. However, in the study by Tonttila et al,30 4 csPCa
cases would have beenmissed if only a targeted approach had been used (ie, the MRI plus targeted
Figure 3. Study Designs of the Included Randomized Clinical Trials
Design B
MRI No MRI
MRI positive MRI negative
Targeted
biopsy
Patients with clinical 
suspicion of prostate cancer
Systematic
biopsy
Systematic
biopsy
Porpiglia et al,29 2017
Design E
MRI No MRI
MRI positive MRI negative
Targeted
biopsy
Patients with clinical 
suspicion of prostate cancer
Baco et al,25 2016; Panebianco et al,27 2015; Park et al,28 2011
Systematic
biopsy
Systematic
biopsy
Systematic biopsy with 
or without ultrasound- 
targeted biopsy
Design A
MRI No MRI
MRI positive MRI negative
Targeted
biopsy
Patients with clinical 
suspicion of prostate cancer
No biopsy Systematic
biopsy
Kasivisvanathan et al,26 2018
Design D
MRI No MRI
MRI positive MRI negative
Patients with clinical 
suspicion of prostate cancer
Systematic
biopsy
Systematic
biopsy
Systematic
biopsy
Tonttila et al,30 2016
Systematic
biopsy
Design C
MRI No MRI
MRI positive MRI negative
Targeted
plus
systematic
biopsy
Patients with clinical 
suspicion of prostate cancer
Systematic
biopsy
Systematic
biopsy
Plata-Bello et al,31 2018 (order of targeted biopsy and 
transrectal ultrasonography not reported)
Designs A and B allowed for sufficient data extraction to analyze the systematic biopsy
alone pathway vs the magnetic resonance imaging (MRI) plus targeted biopsy pathway.
Design C allowed for sufficient data extraction of the systematic biopsy alone and the
MRI plus targeted and systematic biopsy pathways, but not theMRI plus targeted biopsy
pathway because separate data were not reported for the content of targeted and
systematic biopsy prostate cores. Designs D and E allowed for sufficient data extraction
of the systematic biopsy alone, MRI plus targeted and systematic biopsy, and MRI plus
targeted biopsy pathways, except for the study by Panebianco et al,27 which did not
separately report the content of targeted and systematic biopsy prostate cores.
Randomized clinical trials with design E performed targeted biopsies on the basis of
digital rectal examination or ultrasonography findings, whichmay have resulted in an
improved prostate cancer detection in the systematic biopsy alone pathway compared
with other study designs.
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biopsy pathway), which would have resulted in underdiagnosis in 10% of patients with positive MRI
findings.
Inmost RCTs, it was not possible to assess the risk of complications associatedwith the targeted
biopsy procedure compared with systematic TRUS-guided biopsy, because the individuals in the
prebiopsy MRI group underwent systematic sampling during the targeted biopsy procedure. In only
2 RCTs26,29 was the acquisition of targeted cores not combined with systematic sampling. However,
the RCT by Porpiglia et al29 is ongoing, and there are plans to report on complications in future
publications. Kasivisvanathan et al26 reported fewer overall complications for individuals in the
prebiopsyMRI group compared with individuals in the systematic biopsy alone group. The frequency
of hematuria (30% vs 63%), hemoejaculate (32% vs 60%), rectal bleeding (14% vs 22%), erectile
dysfunction (11% vs 16%), and pain at the site of the procedure (13% vs 23%) were each reported to
be lower in individuals in the prebiopsy MRI pathway compared with the systematic biopsy alone
group.26 However, in the prebiopsy MRI pathway, this RCT used both transperineal and transrectal
approaches and only transrectal biopsies in the systematic biopsy alone group, which may account
for the reduced complications in theMRI pathway.Moreover, approximately one-half of individuals in
the prebiopsy MRI group did not undergo a biopsy at all (in the context of the MRI findings being
negative); therefore, this would naturally have reduced the risk of complications in this group of
the study.
We calculated the percentage of individuals for whom a biopsy was avoided, or could
theoretically have been avoided, if the menwith mpMRI-negative findings had not undergone
prostate biopsy. The percentage of men whomay have avoided a biopsy procedure ranged from
23%27 to 55%,31 with an overall estimate of 33% for all 7 RCTs25-31 (95% CI, 23%-45%; I2 = 91.8;
eFigure 1 in the Supplement). In 6 RCTs,25-30 theMRI plus targeted biopsy pathway would also
Figure 4. Detection Rate of Clinically Significant Prostate Cancer
Weight,
%
Favors
Systematic
Biopsy Alone
Favors MRI 
Plus Targeted and 
Systematic BiopsyStudy RR (95% CI)
.1 101
RR (95% CI)
MRI followed by targeted and systematic biopsyA
Baco et al,25 2016
Biparametric MRI
0.78 (0.55-1.09) 100.00
Subtotal 0.78 (0.55-1.09) 100.00
Panebianco et al,27 2015
Multiparametric MRI
1.95 (1.73-2.20) 31.59
Park et al,28 2011 2.80 (0.98-7.98) 14.55
Plata-Bello et al,31 2018 0.76 (0.49-1.18) 26.41
Tontilla et al,30 2016 1.09 (0.74-1.61)
1.36 (0.79-2.34)
27.46
Subtotal (I2 = 87.2%, P = .00) 100.00
Weight,
%
Favors
Systematic
Biopsy Alone
Favors MRI 
Plus Targeted
BiopsyStudy RR (95% CI)
.1 101
RR (95% CI)
MRI followed by targeted biopsyB
Baco et al,25 2016
Biparametric MRI
0.78 (0.55-1.09) 100.00
Subtotal 0.78 (0.55-1.09) 100.00
Kasivisvanathan et al,26 2018
Multiparametric MRI
1.43 (1.10-1.87) 33.66
Park et al,28 2011 2.80 (0.98-7.98) 11.66
Porpiglia et al,29 2017 2.38 (1.50-3.77) 26.67
Tontilla et al,30 2016 0.92 (0.60-1.41)
1.57 (1.02-2.41)
28.01
Subtotal (I2 = 70.7%, P = .02) 100.00
Risk ratios (RRs) are represented by boxes, with the
size of each box representing its weight. Horizontal
lines represent 95% CIs. Diamonds represent
combined-effect estimates and their 95% CIs. MRI
indicates magnetic resonance imaging.
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theoretically have reduced the number of biopsy cores taken per procedure by 77% (95% CI,
60%-93%) comparedwith the systematic biopsy alone group. Themedian number of targeted cores
ranged from 1 to 6, compared with a mean number of systematic biopsy cores in the systematic
biopsy alone group ranging from 11 to 12.
Overall, 31% (95% CI, 15%-49%; I2 = 87%) of PCa cases were not visualized at prebiopsy
mpMRI in 5 RCTs27-31 (eFigure 2A in the Supplement), andmost were classified as clinically
insignificant (according to a systematic biopsy28-31 or saturation biopsy27). In these 5 RCTs,27-31 the
risk of a patient having csPCa and a negative MRI findings ranged between 0% and 23% (eFigure 2B
in the Supplement).
Discussion
This systematic review andmeta-analysis demonstrates that the use of prebiopsy mpMRI combined
with a targeted biopsy is superior to a systematic biopsy alone in diagnostic pathways for PCa. This
improvement is seen in terms of increased detection of csPCa and a reduced number of biopsy cores
obtained during a biopsy procedure, potentially preventing unnecessary biopsies and possibly
reducing the overall burden of adverse effects from the invasive biopsy procedure. This observation
adds to the evidence suggesting that the incorporation of prebiopsy MRI should be recommended
for diagnostic pathways for suspected PCa. Obtaining systematic cores in addition to the targeted
cores during a biopsy procedure did not seem to improve detection of csPCa, and only a few PCas
were missed. However, data in this area were sparse, and studies may have been underpowered to
test this, whereas some level of misclassification could not be ruled out.
To our knowledge, this is the first systematic review to compare 2MRI pathways (MRI plus
targeted and systematic biopsy andMRI plus targeted biopsy) with a pathway including systematic
biopsy alone. The main strength of this review is that the inclusion criteria were limited to RCTs,
which permits direct comparison between 2 diagnostic pathways with clinically relevant outcomes,
as opposed to diagnostic cohort studies that can only inform us about test accuracy measures.
Furthermore, all included trials were of high quality with low risk of bias, and there were sufficient
data to conduct a meta-analysis on eachMRI pathway. Extracting data for bothMRI pathways from
within the MRI plus targeted and systematic biopsy group of some RCTs allowed for direct
comparisons between these pathways, even though none of the RCTs was designed to compare
these 2 pathways per se.
Limitations
Limitations of this meta-analysis include the fact that we were unable to assess publication bias or
perform a meta-regression analysis to test for variables associated with PCa detection because of
insufficient data. The design of the included studies did not allow for calculation of test properties,
such as sensitivity and specificity, because most patients did not undergo a reference standard
procedure (ie, saturation biopsy or prostatectomy). Test accuracy measures were beyond the scope
of this review, but a systemic reviewwill be published soon.32
Two RCTs27,29 did not use identical biopsy approaches for all patients in both study groups.
Some patients in the prebiopsy MRI group underwent biopsy using a transperineal approach,
whereas all patients in the systematic biopsy alone group underwent biopsy using a transrectal
approach. The transrectal approach can be less adequate than the transperineal approach in terms
of sampling the apex and anterior regions of the prostate. Some of the MRI-guided biopsies were
performed through the transperineal approach, which permits better sampling of the apex and
anterior regions of the prostate gland. This may have inflated the cancer detection rates in the
prebiopsy MRI group. However, because of the limited number of RCTs included, it was not possible
to perform a sensitivity analysis on the type of biopsy approach used.
An important limitation of the included RCTs was that each study used a different definition of
csPCa, and it was not possible to extract sufficient data for a standardized definition. This may
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explain the high degree of heterogeneity among studies, whichmeans that results should be
interpreted with some caution. Another source of variation was the guidance method used during
the biopsy procedure itself. Cognitive guidance is potentially more error prone than
MRI-ultrasonography image fusion guidance,33 and the 2 RCTs28,30 using cognitive guidancemissed
the highest percentage of csPCa. Only 1 RCT26 reported data on complications associated with
biopsy; therefore, we have very limited data for this important outcome. None of the RCTs reported
long-term follow-up data to capture screening-relevant outcomes, such as time to mortality or
cancer-associatedmortality.
There have been concerns about the financial costs of MRI, but these have reduced over time,
and 2 recent studies34,35 based on US and UK data have demonstrated that incorporating MRI can be
cost-effective, especially because doing somay avoid some unnecessary biopsies and reduce the
burden of overtreatment. Another concern has been the availability of the necessary expertise to
interpret MRI scans and performMRI-guided biopsies. Training is necessary for radiographers to
perform high-quality mpMRI scans and for radiologists and urologists to interpret the images and
perform targeted biopsies. Standardized reporting has reduced variation in the interpretation of MRI
scans among radiologists, but this variation is still significant.36 Inaccurate sampling has been
identified as a contributor to reducedMRI performance, even in those individuals undergoing
MRI-ultrasonography fusion prostate biopsy.37
Conclusions
A key issue in the diagnosis and treatment of PCa remains the need to identify clinically significant
disease that requires intervention and to avoid the unnecessary diagnosis of low-risk, low-volume
disease. This systematic review and meta-analysis suggests that introducing prebiopsy mpMRI
followed by a targeted biopsy into a PCa detection pathway may lead to the performance of fewer
biopsies than a pathway using systematic biopsy alone. Such an approachmay increase the likelihood
of detecting csPCa, while reducing the detection of low-risk tumors. Introducing prebiopsy MRI,
therefore, has the potential to transform practice. One RCT26 has demonstrated that this may lead to
fewer complications, and further studies have indicated that this may be a useful cost-effective
strategy. There remain concerns that some csPCa cases may bemissed in individuals with an
increased age-specific PSA level and negative MRI findings. Combining theMRI results with other
measures, such as PSA density (ie, PSA levels adjusted for prostate volume), can potentially decrease
the risk ofmissing these csPCa cases,38 but there are few studies in this area, and this requires further
investigation. Moreover, there is no evidence regarding the impact of a delayed diagnosis of csPCa
after a decision not to perform a biopsy is made on the basis of normal MRI findings in the context of
an increased PSA level. The availability of mpMRI and radiologists and urologists trained to use it
appear to be the only hurdles to overcome in establishing mpMRI and targeted biopsy with
standardized reporting as the recommended diagnostic pathway for men with suspected PCa.
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